{"name":"OBI Pharma, Inc","slug":"obi-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OBI-999","genericName":"OBI-999","slug":"obi-999","indication":"Advanced solid tumors","status":"discontinued"}]}],"pipeline":[{"name":"OBI-999","genericName":"OBI-999","slug":"obi-999","phase":"discontinued","mechanism":"OBI-999 is an antibody-drug conjugate targeting Globo H carbohydrate antigen on cancer cells to deliver cytotoxic payload.","indications":["Advanced solid tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNTnlpX2RtSVBSZ1FuVjFWRXc0SzQzSUR3My0zV1hLeW4zNmFZSjVNYnhYbVlhajUyNW8yVUhzaVMta1FSOWZmOEI0VjVsdld0dktfQS1oelJMMmhiNWRBMGtkZ1IyWndleF9wRUdqWGpyVTNxRXU5SWgxc0o1Yjl2SHA1d2VLT2tJdEFFM0ZQdVBHalZvRUxFelFORDJ5aEdVcWR3dFdhWG5lTmYxRG0taGhiU2ZVSDZ6bXlFS3E1OHJTcHZRSFJaeFY5WDVZTGVjMUN5bVluSk5XSHhkNWEwS1VvSk5Bc0k4NWc?oc=5","date":"2026-01-29","type":"deal","source":"The Jackson Sun","summary":"OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC - The Jackson Sun","headline":"OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPYjZVaTloeWJLNW85dTRzOTVaRWwyaldKTEVRRmh6dXBGM3ZfTHV4eFhDcXVHelpxekJWVUNOcEdaSUFTMl9INGVuZ0lRT0Rtck5IdVFZRWNZMGh3N1BmdERBQ19GcV9maHJENGlHWUQwMVMwWTRJUHM1TXA0Unh1aXZub2wxT1RQSl9ZRWFuY0lzNjFsUlJkNlR1Y2M2TGl6STUyUGdDRkNhb1FWQ3F0cTRzTUthR0FmSUs4Y3BNcl9VeExMMlJfWXgtOFhVRE5TdWlWWGhB?oc=5","date":"2026-01-13","type":"pipeline","source":"BioSpectrum Asia","summary":"Taiwan's OBI Pharma inks agreement US-based TegMine Therapeutics for glycan-targeting ADC - BioSpectrum Asia","headline":"Taiwan's OBI Pharma inks agreement US-based TegMine Therapeutics for glycan-targeting ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"Nature","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - Nature","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPUU42cVZfdG41M3BDdmlSN2txTmpIdnRCU04yMzJHQ2I1dlZralB2Q0hua1FrUGwwUDFmaGExSFR5RTh1R0hGUlRScENYWjRibVNaU19LbDk3dW55QkVNVlN4VGhsMWhHWFh2ZDdWN1VpZmwwYlh5S0xWV1BkWDJDaFVYZ1Z5QzBHN091c3NZVXlPdXNkODFfWnBwRGtfWTd5amJTUE9RbFdPZ2xLVGNCQjdxSk85NExCeTN6cVZBVEdZdURHRXNldEI4Tm0zeDg4MmdTamNkMFBxckRXQ0VxQmZldi1NQUpNdHlCZEFn?oc=5","date":"2026-01-12","type":"deal","source":"ACN Newswire","summary":"OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC - ACN Newswire","headline":"OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9JbGdnSWVZT2I4VmlaY3dTUzdGN3hmV1A1V2ExTkVBdGxoOEY1dEx4SVNrWGVLajRiMkZXelh4LUdWampJcEpwdExGVWpxbng2elNUcWFEbmFUUDdJVHExU2V5T2dkcVpCZVpZdXZXNjUxRUpwLThMeTBwaTNTQjg?oc=5","date":"2025-09-02","type":"trial","source":"Yahoo Finance","summary":"OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors - Yahoo Finance","headline":"OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNb1oxRnMxclhVZTJDZW1jYV9yUGQzS3czVVJWdTltall3bFhzSm1RSjF1cEtDd2xSYmg2Nm1xaFR2SFpkYm1uUDBEdEF3NGhjcTIycXY1aExRcEw0VEoyeXZxTnBqakVQbmNEeG9kdldxQ3Y3cjVKQmRtY1A4d05XNGg4dnpCcTBNY3VUOFVuTjZrdw?oc=5","date":"2025-07-01","type":"pipeline","source":"BioSpectrum Asia","summary":"Taiwan's biotech gathers momentum - BioSpectrum Asia","headline":"Taiwan's biotech gathers momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNRnBOcGx6OWNZbF9zQTlQLUtLWmVuMjhtSDRnUFFpTXRzdjI5c1dKWThxSkN3RVhQNkdURFlaSkRJLWhab0lmeXFnWnp4R3NPMjA5SWhhdWJaWjhIUXJvWnB2Tjh4RFZVdS1ZVVJaQURBVThWM2hKOWZONnB3b0ZiTG5tcklsVWVEZVkyVTJhdk1zanZFZXB4S0pwdy1VT0ZoYlRqTnk4cEx3ZmNHTWVudFNjSEtCZUU4Z3V1TXd2Rzd4Nm1FUXl0YnpMU0tEcjVYQnBFWWJSSlREY2JPSjJCVnZuekhIUEZBR1ltQmpIbmJqb2NPYkdtdnExdzZScW9uNXRfV1dZSHp4YXVRZXVfbmtLcC0?oc=5","date":"2025-06-06","type":"deal","source":"GlobeNewswire","summary":"OBI Pharma Enters ADC Collaboration with TegMine - GlobeNewswire","headline":"OBI Pharma Enters ADC Collaboration with TegMine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQeEpXdHFUWlhDZEdWWmpyeXFNR1FKVkVhdXpySDI5WmRKVVRJeEloUEFPTXEzRFdxVkluVkhEOVByektiY3RUcHJJS1hkSWNuZG9aZThIOXVrekdMZFE1NnhCNnA5em5YYUR5cTItMFd5djNjUTF2ZE5NTU8tMnRLMUloR2htbHhlOXVyNmxKcDFhNURkSDVLTHBmazA5LXpuYkM3SA?oc=5","date":"2025-05-02","type":"regulatory","source":"CancerNetwork","summary":"FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors - CancerNetwork","headline":"FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPY202UjV5MjEyTDdVQ1M1bkxaRUJuSmZ0Y2FUTDFwd2NDQWdPd3RNRjJ3VkZNU3JBdzYxc0tCNGxtendhMlNRbnRaamZPTnJXT3RjbEdJZjJNSDkwa0FYOFNvWllIWmM0eVR5ZjJTa1JqakZycHloTHRSZzdRSlJubEI0WElfMmRFYVVFeDJ1aFFwUkdHakVwR2l1V1k2TTMxU1E1bVpTc2lnbzBOVGxkdWM4ZHFmS2dQU2pGTHpOZm9MME1zUXVILTdiVExjallJem5jb3F2akZoUURqWGoyOFp2eWxtcVVfeUhaWFhxMkhnSDNOLWN1MW80SkpUTnhlT3NpV2RSaUpnbmFmY0I5SG5kQQ?oc=5","date":"2025-04-30","type":"regulatory","source":"GlobeNewswire","summary":"OBI Pharma Announces U.S. FDA Clearance of IND Application - GlobeNewswire","headline":"OBI Pharma Announces U.S. FDA Clearance of IND Application","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBPdHhZU0NYUTBSN1huR2RFbE0tcVRaWWs0NHpyZm1DaGtYQTlZd3dHLW1NcVliVVlpWlF3UEtIM1lIUGF6REdWQzJNRzhFZW5QbWVQNnE4azY4WS1KbDJUbExFN3pmN3pPZEJzTTlnWmE?oc=5","date":"2025-03-05","type":"pipeline","source":"Labiotech.eu","summary":"The 7 hottest biotech companies in Taiwan - Labiotech.eu","headline":"The 7 hottest biotech companies in Taiwan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNN25JNG1BWjBheF85Xy1NSlZEVk5nTGZrWFgxZXROOGM0LVVJWW94ODJBV3BveWIzZjEwUjlFZklpQzd1OWcxbnp5d1YzSjkyTDFJbU96UTJIb01JVkt0TG1JTFJabkNSRWdhWjB5SmNYRkhmTXFCSUVzRDNtZ1NoZnVPVF9BalJhRVNuRmpQTk81dDZucWVmYml5OTZoTDdLY0E?oc=5","date":"2025-01-16","type":"pipeline","source":"BioWorld News","summary":"OBI-992, a TROP2-targeted ADC with strong antitumor activity - BioWorld News","headline":"OBI-992, a TROP2-targeted ADC with strong antitumor activity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQQVFqNHZWMHlfWXhEMHVnVjN6U3hhb2JBRi02alZxR0c5eTZucE0yUHA5aTZrWUotcHRhNnJ4dDBtLWpHbnNoZFhKQ3JQNjJOZXRsSFZUY3VyZDVEQ1hPNzJucDg1djZMM2UtbEYtTWNxYUh6VmNyU3VBQzVzVTZ2Tw?oc=5","date":"2020-08-23","type":"pipeline","source":"marketscreener.com","summary":"OBI Pharma, Inc.: Shareholders Board Members Managers and Company Profile | TW0004174008 - marketscreener.com","headline":"OBI Pharma, Inc.: Shareholders Board Members Managers and Company Profile | TW0004174008","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}